Opens testing access to the largest state-run health plan in the United States
IRVINE, CA, and HERSTAL, BELGIUM – September 6, 2016 – MDxHealth SA (Euronext: MDXH.BR) announced that the ConfirmMDx® for Prostate Cancer test is now available as an in-network benefit under the California Medical Assistance Program (Medi-Cal).
Medi-Cal is California’s state-run Medicaid program, offering assistance to individuals with low incomes. With nearly 12 million enrollees, it is the single largest state-run public health program in the US. The agreement extends access to ConfirmMDx for all Medi-Cal beneficiaries meeting the test eligibility requirements. The Company will now seek to expand access to the test through other Medicaid programs across the US.
“This agreement enhances our ability to deliver state-of-the-art diagnostic testing to all sectors of the healthcare system in California, the largest economy and most populous state in the US,” stated Dr. Jan Groen, CEO of MDxHealth. “This agreement provides a model for further expansion of coverage in the US as health providers increasingly recognize the ability of ConfirmMDx to improve patient outcomes and help manage rising healthcare costs.”
About ConfirmMDx for Prostate Cancer
ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer which addresses false negative biopsy concerns. It is the only molecular diagnostic test that provides a very high negative predictive value (NPV) of 96% for clinically significant prostate cancers, and 90% NPV for all prostate cancers, as well as prostate mapping of the test results to help guide repeat biopsies. Each year, more than 1 million American men undergo an invasive prostate biopsy with a negative result, however approximately 30% of those men actually have prostate cancer. The current standard of care for prostate biopsy procedures samples less than 1% of the prostate, leaving men at risk for undetected cancer and leading to a high rate of repeat biopsies, even on cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. To date nearly 2,800 urologists have ordered ConfirmMDx on more than 45,000 patients. ConfirmMDx has qualified for Medicare, Medicare Advantage and many private reimbursement plans.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com
Jonathan Birt, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)
mdxhealth@consilium-comms.com
